Irma Bagdoniene: Lowering LDL May Alter Inflammatory and Oxidative Pathways
Irma Bagdoniene, Cardiologist and Lipidologist at Klinikum Lippe – University Hospital for Cardiology, Angiology, and Internal Intensive Care Medicine, posted on LinkedIn:
“Lowering lipids — but increasing oxidation?
A new study by Koutsogianni et al. (2025) looked at people with high Lp(a) and found something unexpected:
– Statins and ezetimibe raised oxidized phospholipids on apoB and apo(a), reduced those on plasminogen,
– while PCSK9 inhibitors had no clear effect.
So even when we lower LDL cholesterol, other inflammatory and oxidative processes may change in ways we don’t yet understand.
The message is clear: we need more studies to understand how lipid-lowering therapies truly affect the biology of Lp(a).”
Title: Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a)
Authors: Amalia Despoina Koutsogianni, Fotios Barkas, Constantinos Tellis, Alexandros Tselepis, George Liamis, Sotirios Tsimikas, Evangelos Liberopoulos
Read full article here.
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI